# Three Compounds, Three Very Different Evidence Tiers

> Retatrutide vs MOTS-c vs KPV: Evidence Compared — peptideradar — A side-by-side comparison of three emerging-pipeline research peptides — retatrutide, MOTS-c and KPV — across mechanism, evidence maturity, human data, regulatory status and the single most important caution for each.

**EMERGING PIPELINE / MATRIX**

Retatrutide, MOTS-c and KPV share a status — unapproved — and almost nothing else. Here is where each one actually stands.

## The short version

The three peptides on this desk are often filed under the same heading — *emerging research peptides* — and that heading hides more than it explains. [Retatrutide](/retatrutide) has been tested in randomised trials in hundreds of people and produced large, measured effects [4][5]. [MOTS-c](/mots-c) has been tested mainly in mice, with one small human cohort that merely observed the peptide people already had circulating [9][11]. [KPV](/kpv) has never appeared in a published human trial at all [15][16].

So when a comparison table sets them side by side, the useful column is not potency. It is **evidence maturity** — how close each compound is to having answered the question *does this work in people, and at what cost*. On that axis the three are separated by years and by tiers, not by inches. Only one of them has a documented adverse-effect profile, and that is not because the other two are gentler. It is because nobody has run the study that would find out.

## The comparison matrix

| Dimension | Retatrutide | MOTS-c | KPV |
| --- | --- | --- | --- |
| What it is | 39-amino-acid synthetic peptide, C20 fatty-diacid acylated | 16-amino-acid peptide encoded in mitochondrial DNA (MT-RNR1) | 3-amino-acid tripeptide; C-terminal fragment of alpha-MSH |
| Primary targets | GLP-1R, GIPR and GCGR simultaneously [2] | AMPK via folate-cycle inhibition; CK2 as a direct binding partner [8][10] | PepT1 transport; NF-kB and MAP-kinase suppression [15] |
| Highest evidence tier reached | Randomised controlled trials in humans (Phase 2 complete, Phase 3 ongoing) [1][4][5] | Observational human cohort; interventional data animal-only [9][11] | Animal and in vitro only [13][14][15][16] |
| Studied mainly in | Obesity, type 2 diabetes, metabolic liver disease [3][4][5] | Metabolic regulation, exercise capacity, muscle ageing [8][11] | Intestinal inflammation and colitis models [13][14][15][16] |
| Human interventional data | Yes — hundreds of participants across Phase 1b and Phase 2 [4][5][6] | None published | None published |
| Human pharmacokinetics | Half-life approximately 6 days, measured [6] | Not established | Not established |
| Regulatory status | Investigational; not approved by any regulator as of 2026 [1] | Not FDA-approved; research chemical, laboratory use only | Not FDA-approved; research chemical, laboratory use only |
| Anti-doping standing | Not specifically prohibited; investigational status can change classification | Treated as prohibited in elite sport | Not specifically listed by name |
| Documented adverse effects | Dose-dependent GI events; heart-rate increase; lean-mass loss [4] | Unknown — never assessed in a controlled human trial | Unknown — never assessed in a controlled human trial |
| Single most important caution | Large effects, but no Phase 3 or outcomes data and no approval [1] | Mechanism far better established than effect [9][10] | Empty clinical record; delivery problem unsolved [13][14] |

## Mechanism: no common ground

There is no shared pathway across these three, and any framing that implies one is wrong. Retatrutide is a receptor agonist acting on the incretin and glucagon axis from outside the cell, with all three receptor engagements resolved structurally [2]. MOTS-c acts inside the cell on a metabolic sensing pathway and additionally travels to the nucleus to change gene expression [12]. KPV acts inside epithelial cells to suppress inflammatory transcription after being imported by a nutrient transporter [15].

The scales differ as sharply as the routes. Retatrutide changes whole-body energy balance. MOTS-c adjusts cellular fuel-sensing, most visibly in skeletal muscle. KPV modulates a local inflammatory response in tissue. These are three different levels of biological organisation, and results at one level say nothing about the others.

The one honest generalisation available is chemical: all three are short peptides, and all three face the same problem of surviving long enough in the body to act. Retatrutide solved it with a fatty-acid tail that binds albumin and buys a six-day half-life [6]. MOTS-c has no published human answer. KPV's answer, so far, is nanoparticles and hydrogels in mice [13][14].

## Evidence maturity: the axis that matters

Retatrutide sits at the top of the ladder available here, and its numbers come from designs that can support them: 338 adults randomised in the Phase 2 obesity trial, 281 in the Phase 2 diabetes trial, 98 in the liver-fat substudy, each with a placebo comparison [3][4][5]. That does not make it proven — Phase 3 has not reported and no outcomes trial has read out [1] — but it makes its effect estimates real measurements rather than inferences.

MOTS-c sits two rungs down. Its functional evidence is rodent [8][11], and its human evidence is a 94-participant observational cohort in haemodialysis patients where the hazard ratio was 1.004 at a p-value of exactly 0.05 [9]. That is a borderline association in a small, atypical population, measuring the endogenous peptide rather than an administered one.

KPV sits at the bottom rung, with consistent results across independent mouse colitis models and across twenty years [15][16][17], and no human data of any kind.

The asymmetry worth sitting with is this: the compound with the best evidence also has the longest list of documented harms [4]. That is not a mark against retatrutide. It is what happens when a compound is finally studied properly — the harms become visible. A blank safety record is what an unstudied compound looks like, and reading it as reassurance inverts the meaning of the data.

## What none of them has

Three absences apply across the board, and they are the reason this hub exists.

**No approval.** Not one of the three is an approved medicine in any jurisdiction. Retatrutide is investigational and confined to clinical trials [1]; MOTS-c and KPV are research chemicals sold for laboratory use.

**No verified supply outside the regulated channel.** Material sold through gray-market research channels is not manufactured to pharmaceutical standards, and analyses of comparable peptides have found truncated sequences, altered stereochemistry and misidentified contents. Without sterility and endotoxin testing there is no way to know what is in a vial, and that risk is identical for all three compounds regardless of their evidence tier.

**No long-term data.** Retatrutide's outcome trials are ongoing and unreported [1]. MOTS-c and KPV have never had a long-term human study to begin. For a class of compounds whose proposed uses are chronic rather than acute, that gap is the single largest unknown on this page.

What a reader can take from the comparison is narrow and, this desk would argue, worth more than a ranking: retatrutide is a compound with real measured effects and real measured costs, awaiting the trials that decide its fate; MOTS-c and KPV are interesting biology that has not yet been asked the clinical question. Anything stronger than that is not supported by the sources listed on the [references page](/references).

---

peptideradar is an independent literature digest on unapproved research peptides that reports where the evidence stops rather than where the marketing starts — not a clinic, not a vendor, and not medical advice.